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Reducing cell–cell stickiness with JAM-C
Most cell junction proteins increase endothelial cell–cell adhesion. But junction 
adhesion molecule-C (JAM-C), despite its sticky name, loosens vascular endothelial 
cell connections, thus allowing increased blood vessel permeability.
Increasing the permeability of small blood vessels is essential for new vessels to form 
and for leukocytes to escape the circulation and enter surrounding tissues during 
inflammation and tissue repair. Permeability is thought to be controlled by tight 
junctions between neighboring cells. Most tight junction components promote cell–
cell adhesion and thus reduce permeability. But Orlova et al. (page 2703) show that the 
tight junction protein JAM-C does the opposite—it promotes permeability. Indeed 
JAM-C is the first junctional molecule reported to behave this way.
Using dye tracking, the team showed that knocking down JAM-C reduced 
endothelial permeability both in vitro and in vivo. The permeability-promoting 
effect of JAM-C was not on tight junctions themselves, but rather on a different 
type of cell–cell junction called adherens junctions, which contain the adhesion 
protein VE-cadherin. Knocking down JAM-C led to increased adhesion between 
VE-cadherin molecules at cell junctions. Such increased interaction is thought to trigger, via 
junction-associated factors, a series of steps that ultimately promotes actin depolymerization—thus 
further reducing permeability, as cells are unable to contract and pull apart. Consistent with this 
theory, knocking down JAM-C also reduced intracellular actin polymerization.
That a molecule from one type of junction can promote permeability by acting on another type of 
junction was surprising. The team found, however, that JAM-C increased endothelium permeability 
whether located at the cell junctions or diffusely distributed in the cytoplasm, indicating that JAM-C might 
be a signaling as well as structural protein, though the authors have yet to investigate this possibility.
One of the many more typical tight junction molecules that reduce vessel permeability is JAM-A, 
a closely related family member of JAM-C. How two such structurally similar junction molecules 
can have opposing effects on blood vessel permeability remains to be determined. 
Bone destruction by Th17
T cells that produce cytokine IL-17 activate bone-destroying osteoclasts, report Sato 
et al. on page 2673. The finding pinpoints a potentially powerful target for autoimmine 
arthritis therapy.
Autoimmune arthritis, such as rheumatoid arthritis, is a T cell–driven disease, in which 
bones are destroyed by hyperactive bone-resorbing osteoclasts. Activated T cells have long 
been implicated in arthritic inflammation and the resulting bone destruction, but exactly 
which type of T cell is responsible has never been confirmed. T helper (Th)-1 cells, the cells 
that promote cellular immunity, have received the lion’s share of the blame. Yet Th1’s 
signature cytokine, IFNγ, actually inhibits bone resorption by osteoclasts.
The study by Sato et al. helps resolve this paradox by putting the blame for 
inflammatory bone destruction on a recently described T cell subset called Th17. Th17 
cells, named for their propensity to secrete the cytokine IL-17, have also been 
implicated in other models of autoimmune inflammation.
The team tested whether various T cell subsets—Th17, Th1, Th2, and regulatory 
T cells—affected osteoclasts. They found that only Th17 cells enhanced osteoclast 
differentiation—a prerequisite for bone resorption. IL-17 itself also promoted osteoclast 
differentiation. The induction of osteoclast differentiation was only seen when bone-
forming osteoblast cells were also present in the culture. Osteoblasts provide 
osteoclasts with differentiation signals; thus it now appears that IL-17 might prompt 
the osteoblasts to release these signals.
Current treatments for autoimmune arthritis reduce inflammation by using broad-
based immunosuppression. The identification of both the specific T cell subset and the 
cytokine responsible for promoting bone resorption might lead to a more powerful 
therapy that also targets skeletal damage. 
Bone destroying cells (red) flourish in the 
presence (top) of the IL-17 cytokine. 
JAM-C (green) loosens cell junctions (red) 
to increase blood vessel permeability.